文献速递肝病消化道肿瘤与早癌

综述:晚期肝细胞癌的新型治疗干预

Review article: new therapeutic interventions for advanced hepatocellular carcinoma.
PubMed 文献 · Aliment Pharmacol Ther · 2019-11-20

本综述汇总了晚期肝细胞癌(HCC)一线与二线治疗临床试验,指出索拉非尼后已有仑伐替尼等一线选择及瑞戈非尼、卡博替尼、雷莫芦单抗等二线选择,免疫检查点抑制剂Ⅱ期显示持久客观缓解但Ⅲ期未改善生存,联合方案仍在探索。

要点

  • 仑伐替尼一线生存非劣于索拉非尼,为另一线治疗选择。
  • 瑞戈非尼、卡博替尼在索拉非尼失败后二线显著改善生存。
  • 雷莫芦单抗二线可改善AFP≥400 ng/dL患者生存。

核心结论

  • 晚期HCC已有多个一线和二线治疗选择,仍需研究如何选择与排序。

研究设计与样本

  • 综述PubMed发表或全国会议报告的晚期HCC临床试验。

主要发现

  • 索拉非尼2007年获批不可切除HCC,多年为唯一有生存获益的晚期HCC治疗。
  • 仑伐替尼与索拉非尼相比生存非劣,为另一线治疗选择。
  • 瑞戈非尼和卡博替尼在索拉非尼失败后二线显著改善生存。
  • 雷莫芦单抗二线可改善AFP≥400 ng/dL患者生存。
  • 免疫检查点抑制剂Ⅱ期显示持久客观缓解,nivolumab和pembrolizumab获FDA二线条件批准,但Ⅲ期未显示生存优于其他治疗。

关键数值与推荐

  • 索拉非尼2007年获批用于不可切除HCC。
  • 雷莫芦单抗二线改善生存限于AFP≥400 ng/dL患者。

临床怎么用

  • 晚期HCC一线可选索拉非尼或仑伐替尼。
  • 索拉非尼失败后二线可选瑞戈非尼、卡博替尼,AFP≥400 ng/dL可考虑雷莫芦单抗。
  • 免疫检查点抑制剂二线应用需结合Ⅲ期阴性结果谨慎评估。

局限性

  • 综述未报告检索时间范围与纳入试验数量。
  • 免疫联合方案疗效尚待 ongoing 试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced hepatocellular carcinoma (HCC) portends a poor prognosis; however recent advances in first-line and second-line treatment options should yield significant improvements in survival. AIM: To summarize the evolving landscape of treatment options for patients with advanced HCC. METHODS: We reviewed published clinical trials conducted in patients with advanced HCC published in PubMed or presented at national conferences. RESULTS: Sorafenib was approved for treatment of unresectable HCC in 2007 and remained the only therapy with proven survival benefit in advanced HCC for several years. Lenvatinib, another tyrosine-kinase inhibitor, was recently shown to have non-inferior survival vs sorafenib and is another first-line treatment option. The tyrosine-kinase inhibitors, regorafenib and cabozantinib, were shown to significantly improve survival in the second-line setting after sorafenib failure. Ramucirumab, a VEGF inhibitor, can also improve survival in the second-line setting among patients with AFP ≥ 400 ng/dL. Phase II data highlight potential durable objective responses with immune checkpoint inhibitors, prompting conditional FDA approval of nivolumab and pembrolizumab in the second-line setting; however, recent phase III data have failed to demonstrate improved survival compared to other treatment options. Ongoing trials are evaluating combination immune checkpoint inhibitor and immune checkpoint inhibitors with tyrosine-kinase inhibitors or VEGF inhibitors in hopes of further increasing objective responses and overall survival in this patient population. CONCLUSION: There are several first-line and second-line therapeutic options available for patients with advanced HCC. Further studies are needed to determine how best to select between and sequence the growing number of therapeutic options.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Bangaru S, Marrero JA, Singal AG, et al. Review article: new therapeutic interventions for advanced hepatocellular carcinoma. Aliment Pharmacol Ther. 2019. PMID: 31747082. doi:10.1111/apt.15573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。